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A Chromogenic Tesl to Determine the Procoogulont
Phospholipids inPlqtelet-rich Plosmo ond Whole Blood
R, J, Wogenvoord, H, H, Hendrix, Hu Koi,  H, C, Hemker
From the Deportment of Biochemistry, Foculty ll. University of Limburg, Moostricht, The Netherlcnds
Summory
We have developed a chromogenic assay t0 measure the phospho-
lipid-related procoagulant activity (PPA) in whoie blood, or platelet-
rich plasma. The test is based upon thrombin formation from
prothrombin by prothrombinase and is designed in such a way that
procoagulant lipids are rate limiting for the prothrombinase activity. In
the chromogenic test PPA concentrations equivalent o 0-10 nM
phospholipid vesicles containing 75% phosphatidyl choline (PC) and
2570 phosphatidyl serine (PS) can be measured.
The thrombin, which develops during the test, is measured with a
chromogenic substrate. By the action of thrombin on this chromogenic
substrate p-nitroaniline is liberated, which causes an increase in ab-
sorbance. Thrombin formed in the assay mixture activates the present
platelets. This causes a linear increase of the velocity of thrombin
generation during the test, i. e. a parabolic increase of product fomation.
For that reason the thrombin generation i time is characterized by two
parameters, the basal PPA (PPA-B) of the original mixture and the
increase in PPA due to platelet activation (PPA-A). To determine these
figures the absorbency-data were fitted to parabolas. In most cases the
contribution of PPA-A to the total amount of formed thrombin becomes
considerable already after 30 s.
Preliminary tests show that PPA-B activity in whole blood or
plateletrich plasma of patients with a thrombotic disorder is signifi-
cantly higher than the activity of a control group of the same age.
Inlroduction
The role of platelets in hemostasis i  complex. Traditionally adhe-
sion and aggregation are said to cause primary hemostasis, providing a
platelet plug that later is reinforced by thrombin mediated coagulation
of fibrinogen. However, thrombin formation and platelet reactions are
intricately interwoven, because thrombin induces platelet aggregation
and activation, whereas platelets in contact with tluombin and collagen
expose procoagulant phospholipids ( I -4) Also the intercellular spaces
in a platelet aggregate will contain stagnant plasma, enriched in factor
V released by the platelets. In this stagnant plasma high concentrations
of activated clotting factors (e. g. thrombin) can be built up without
being diiuted by flow processes.
The role of procoagulant phospholipids in thrombin generation is
pivotal. Thrombin is formed from prothrombin by factor X,, and factor
Xu is formed by activation of f'actor X with factor IX", Both reactions
are so slow as to be practically nil under physiological conditions in
Conespondence [o:Dr. R. J. Wagenvoord, Deparlment of Biochemisry, Fa-
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the absence of procoagulant phospholipids (5-11). A procoagulant
phospholipid sudace is obligatory for physiologically significant
thrombin formation. A surface will only be procoagulant when a
sufficient amount ofnegatively charged phospholipids (mostly PS) are
present (1). The outer leaflet of the membrane of a resting platelet
contains hardly any PS ( 1, 2) Therefore it is hardly or not procoagulant.
On activation of the platelet he PS present in the inner leaflet of the
membrane will be translocated to the outer ieaflet (1-4). This is the
so-called flip-flop reaction and by this process the platelet will become
procoagulant. Platelets can be activated by the natural activators throm-
bin and collagen, but also by calcium ionophore A23181 (12), diamide
(1) and several other compounds. Because platelets are activated by
thrombin, this enzyme facilitates its own formation. This is not the
only positive feedback loop in the coagulation process. The factors V"
and VIII^, which are required for optimal activation of prothrombin and
factor X, respectively, arise from thrombin action upon their plasmatic
precursors factors V and VIII.
The level of activated clotting factors in whole blood usually is 1ow,
because they are scavenged by a variety of inhibitors in the plasma.
Below a certain threshold these activated factors are not harmful (13).
Also the amount of procoagulant phospholipids exposed in whole blood
is 1ow, because resting platelets have a mechanism that relocates
PS from the outer to the inner leaflet of the membrane (14). A minor
amount of the PS is probably present in the outer leaflet of the
unactivated platelet, causing a residual procoagulant activity. Also
procoagulant phospholipid activity (PPA) may be present in the form of
microvesicles (15) and, to a limited extent, on lipoproteins (16). A high
PPA activity in plasma will probably lower the threshold at which
activated clotting factors will be able to start explosive thrombin
generation, which, in vivo will probably be an important step in
developing thrombosis. Thus the susceptibility of a person to get
thrombosis may very well be conelated with the level of procoagulant
activity of his blood, be it on the platelets or elsewhere.
Apart from the basal PPA activity (PPA-B) that is thought to be pres-
ent in circulating blood, there is the PPA activity generated inblood by
activation of the platelets as soon as the first traces of thrombin are
formed. It can be imagined that this activation-related part of the
PPA (PPA-A) may differ with the status of the platelets in the plasma.
Simply the number of platelets may be important, but also the facility
with which the "flip-flop" reaction is triggered, or the PS content. Some
platelets may be more susceptible to the activating action of thrombin
than others. This may be related to the membrane composition, mem-
brane fluidity, or the presence of platelet inhibitors. It is well possible
that easily triggered platelets cause a higher thrombosis risk than lazy
ones. It therefore may be interesting to be able to test the excitability 0f
a platelet. AIso measuring the excitability of a platelet as a function
of drugs administered to the patient, or added in vitro may serve as a
screening test for potential flip-flop inhibitors. Apart from a high basal
PPA also a rapid generation of PPA by smal1 amounts of activated
clotting factors may represent a thrombotic risk.
It seems desirable to be able to determine both PPA-A and PPA-B in
blood. Because platelets are notodously labile, it is important that this
test can be carried out on whole blood or platelet-rich plasma that has
undergone a minimum of ex vivo manipulations. In this article we
describe such a test To develop this test we have used the property of
the prothrombinase to be critically dependent upon the presence of
procoagulant phospholipids. Also the factor X activating complex has
this property. We have chosen to use prothrombinase as an indicator of
practical reasons: factor \ is stable, in contrast to factor VII\.
Melhods ond Moteriols
Materials
52238 and fibrinogen were purchased from AB Kabi Diagnostica, Stock-
holm, Sweden. Ovalbumin (grade V) and Echis carinatus venom were obtained
from Sigma The purified factor X activator from Russell's viper venom was a
gift from Dr T. Tran (then at Baxter, Diidingen, Switzerland).
All other eagents used were of the highest grade commercially available
Proteins
Bovine factor X was prepared according to Fujikawa et al (17) Factor Xo
was obrained by activation of factor X with Russell's viper venom (18). Bovine
prothrombin was purified according to Owen et al. (1 9) Thrombin was isolated
as is described elsewhere (20) Bovine factor V was isolated according to
Lindhout et al. (21) and factor V, by activation of factor V with 2 nM thrombin
during 60 min at 37' C in the presence of 2 mM CaCl, After isolation all
proterns were dialyzed against l75mM NaCl, 50mM Tris-HCl, pH7.9
(Tris/NaCl, pH 7.9) Dilutions were made in the same buffer plus 1 mg/ml
ovalbumin.
P ho s pho lipids and P ho spltolipid V e s icles
PC and PS were isolated from egg-yolk and bovine brain, respectively, and
purified according to Comfurius andZwaal (22) Vesicles were prepared by
5 min sonication of a phospholipid mixture (in Tris,{'{aCl, pH7 .9) of T5Va PC
and 15% PS using an MSE MarkII 150-Watt ultrasonic disintegrator, set at
9 p peak to peak amplitude Phospholipid concentrations were determined by
analysis of the phosphate content (23).
Blood ColLection
We have noticed that the activity of the platelets in blood depends on the
way the blood is collected. When blood is collected on citrate alone the proco-
agulant activity increases rapidly in time and is markedly higher after t h
When blood is taken on ACD (5 pafis blood are mixed with 1 part ACD, i e
183 mM glucose, 80 mM trisodium citrate, 52 mM cirric acid), however, the
procoagulant activity remains at starting level for at least a few hours
For the above mentioned reasons it is necessary that the blood is collected
on ACD and measured within 2 h. If individual variation between patients has
to be measured, citrated blood may be used, but in this case the procoagulant
activity should be measured within 20 min after blood collection The blood
should be stored at room temperatule and never below 10" C, because in a
number of cases we noticed some activation of the platelets when they were
kept at 4" C.
Preparation of Washed Enthrocttes
Blood (500 pl) was mixed with 10 ml isotonic salt and centrifuged at
100 X g during 10 min The supernatant was discarded and the pellet was
suspended and centrifuged ln the same way two times. Finally the erythrocytes
were centrifuged at 1000 x g during 10 min to obtain packed cells.
Execulion of the PPA-test in PRP or Whole Bktod
The design of the assay is based on data described under Results PRP or
whole blood is diluted 20X in isotonic salt. To 300 pl diluted PRP or blood is
added 300 pl 6 pM prorhrombin (reagent 1) and the mixture is preincubated at
37' C during 5 min Then 300 pl of reagent 2 (prewarmed at37" C), i e. a mix-
ture containing 1 2 nM factor Xo, 1 2 nM factor \, 15 mM CaClr, is added to
start the reaction. At predetermined intervals, samples of 100 p'l are taken and
mixed with 500 pl stop-buff'er. The srop-buffer is TrisiNaCl + 10 mM EDTA
(pH 7.9), or 100 mM ammonium bicarbonate, L0 mM EDTA (pH 8 0). In case
of PRP both stop-buffers can be used, however, to test whole blood only the last
buffer can be used, in which the erythrocytes lyse Lysis of the erythrocytes
takes less than 2 min. Finally formed thrombin is measured by addition of 25 p1
52238 of 2 mM To study the effect of platelet activators or drugs on PRP or
whole blood, this compound is added to the prothrombin and a 5 min pre-
incubation step is introduced. Because the test is for use in a clinic a device for
stinrng the samples was not used The platelet count was determined in the ori-
ginal samples (and not after dilution of the samples) with a Thrombocounter-C
(Coulter Electronics, LTD, Luton, UK), or with the Hematology system of
Technicon Instruments Corporation (Tanytown, NY, USA)
Results
The Chr orno ge ni c - a s s ay fo r P r o c o a gulant P ho sp holip id s
It is known from previous work (Rosing et a1., 9) that linear thrombin
formation is observed when factors X. and V. are added to a mixture
containing prothrombin and phospholipids. The general procedure de-
scribed at "Execution of the PPA-test inPRP or whole blood" was used
to determine the optimal conditions to measure procoagulant phospho-
lipids. We noticed that by using 2 pM prothrombin i  the reaction mix-
ture, the reaction rate is not affected by the decrease of the prothrombin
concentration. Maximally 0.15 pM prothrombin s activated so the re-
sidual amount of prothrombin will be higher than 1.85 pM, which is far
above the Iq, (24) and thus no effect 0n the reaction rate is expected. In
search for optimal conditions it should be considered that factors X.
and Vu have to be present in excess over the amount of binding sites on
the phospholipid. Asa model phospholipid we used vesicles containing
25IoPS andl5Vc PC. Such a vesicle suspension contains about 5 nM
sites for the FX"-FV"-complex per pM phospholipid (24). To determine
optimal conditions to measure procoagulant phospholipids we varied
the FX,-F\-concentration from 0 to 0.8 nM in the reaction mixture and
measured the rate of thrombin formation The rate is proportional with
the FX"-F\-concentration and is very low in the absence of phospho-
lipids (biank). However, this blank becomes ubstantial when the
FX"-FV. concentration is high and phospholipids with low concen-
tration of PS have to be measured. To compromise between ahigh sen-
sitivrty for procoagulant phospholipids and a low blank value we
have chosen for a concentration of 0.4 nM FX"-FV, in the reaction
mlxiure.
Fig. I shows that the rate of thrombin fotmation is linear in time
(inset of Fig. 1) and that the rate of thrombin formation is proportional
with the phospholipid concentration up to about 10 nM (drawn straight
line; y - 2.\1x- 0.161,in which y is the rate of thrombin formation and
x the phospholipid concentration). The rate of thrombin formation is
also linear dependent on the FX,-F\- concentration ( ot shown).
Fig. 2 shows that the procoaguiant activity of isolated platelets
can be measured in a simple way by using the described method. The
platelets were isolated according to van Rijn eI al. (12) The platelets
then were treated with thrombin, with collagen and with thrombin +
collagen. Because n0 Ca2+ was present during pretreatment it was not
expected that the procoagulant activity arose forthwith, but only after
recalcification, i. e. during the experiment.
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The first phenomenon that meets the eye is that the rate of thrombin
formation initially is low, but not zero, and that the velocity is building
up in time with a constant first derivative. To analyze the data in Fig. 2
we have fitted them to parabolas. In this way we found the constants for
the formula T = at2 + bt + c, which were used to draw the curves in the
figure. When no thrombin is added uring pretreatment of the platelets
the curves pass through the origin, c = 0, but when the platelets
were pretreated with ttrombin, 3 nM thrombin is present at t = 0 and
thu$ s = 3. The constant b is the linear part of the thrombin generation,
presgnt f Om zqrodir-ne on, i. e. the basal activity (PPA-B), whereas the
constant ais proportional to the lipear inprease ofthe prothrombinase in
the mixture, 1. e. PPA-A. Fig. 2 shpws that the PPA-B is hardly influ-
enced by the pretrgatment of the platelets, however, the acceieration
(PPA-A) depends on the preffeatment. Pretreatment with 4.5 nM
thrombin, or 10 pg/ml collagen has a minor stimulating effect on the
acceleration, whereas thrombin plus collagen has a much more pro-
nounced effect.
We have measured the activity of untreated platelets as function of
the concentration. Samples were prepared with 0-50 x 10e platelets/l,
and tested as descibed in Fig.2. The result is shown in Fig. 3. It is
noted that the procoagulant activity is linearly dependent on the number
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of the platelets. For this reason it is allowed to compare samples with
different platelet concentrations provided that the found activities are
expressed as activity per number of platelets.
These results show that the procoagulant activity of phospholipids
and the activity that develops in patelets during the test can be meas-
ured in a routine test. However, the isolation of platelets requires afew
hours, may induce activation and thus is not suitable for clinical and/or
epidemiological purposes. For that reason we investigated whether the
procoagulant activity of whole blood could be measured. We noticed
that erythrocytes disturb the thrombin determination, because they
settle in the cuvette during the measuement. To avoid this source of
effor we removed the cells either by centrifugation or by lyses in am-
monium bicarbonate. In this way thrombin can be well measured
provided that the final blood dilution at ieast is 60X in order to avoid
too high background absorption by haemoglobin. Fig. 4 shows that lyses,
executed in this way, and centrifugation of the erythrocytes give com-
parable results. However, the amidolytic activity of thrombin in ammo-
nium bicarbonate buffer is about 80% of that in 175 mM NaCl, 50 mM
Tris-HCl (pH 7.9) due tQ an effect of the salt present (25).
We also have noticed that the erythrocytes do account for a con-
siderable amount of the basai activity (see Table 1). This activity is not
Fis I Fig.2
Flg. 1 Measurement of procoagulant phospholipid vesicles. To 100 pl prothrombin (6 pM, in Tris-buffer, pH 7 9) was added 100 p1 phospholipid vesicles
(25Va PS;1 5Vo PC) diluted in isotonic salt and after 5 min preincubation at37" C 100 pl of 1 2 nM factor Xo, 1.2 nM factor Vu and 15 mM CaCl, in Tris/I.{aCl
(pH 7 9), 0 2% ovalbumin (FX"-F\-Ca-mixture). The phospholipid concentration i  the reaction vessel is indicated in the figure. Samples of 100 pl were taken at
0 5, 1,2,3 and 4 min and mixed with 500 pl 10 mM EDTA + TrisA{aCl to stop the prothrombinase Formed thrombin was measured by addition of 25 pl 52238
(2 mM). In the inset the amount of formed thrombin is plotted against the time. The phospholipid concentration was 0 (-O-), 8.3 (-f-), 167 (-L-),25 (-V-),
33.3 (-O-) and 66.1 Cn-) nM. The slopes in the inset were plotted in the figure
Fig.2 Procoagulant activity of isolated platelets Platelets (600 p.1) were incubated with either 600 pl 6 pM prothrombin (-a-), 600 pl 6 pM prothrombin
+10pg/mlcol lagen(-A-),600pl 6pMprotkombin+9nMthrombin(- l-),or600pl 6pMprothrombin+10pg/mlcol lagen+9nMtkombin(-V-)during
5 min at 37" C, The blank (no platelets) is represented by (-a-). To start the prothrombinase 600 pl FX"-F\-Ca-mixture (see Fig. 1) was added. The platelet
concentration i  the reaction vessel was 4.2 x 10e platelets/l Samples of 100 ml were taken each 15 sec and measured as described in Fig. 1. The symbols in the
figure are the actually measured amounts of formed tluombin, whereas the drawn lines are parabolas with the formula T = at2 + bt + c, in which T is the amount of
thrombin, a, b and c are constants and t is the reaction time. The constants were determined by curve fitting; c was set to 0 when no thrombin was present during
the preincubation and to 3 when thrombin was present during preincubation. The constants are given in the inset; PPA-A = a and PPA-b = b. No conections were
made for the blank
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stimulated by thrombin, collagen, or thrombin plus collagen, which
means that the PPA-A of washed erytlrocytes is close to zero and that
thrombin formation is linear in time.
When PPA is measured in PRP it is not necessary touse the ammo-
nium bicarbonate stop-buffer, but TrisNaCl stop-buffer can be used
also After stopping the reaction with EDTA it is necessary t0measue
Fig. 3 Fig 4
Fig. 3 The procoagulant activity as function of the platelet concentration The procedure described in Fig. 2 was used However, samples were prepared
with 0 (-f-), 12.5 (-O-), 25 (-f-), 37.5 (- -) and 50 (-V-) X 10e cellVl. Because the sample is one third of the reaction volume the concentration f the platelets
in the reaction mixture is 0-16.7 X 10e cells,{ The data were fitted to parabolas as described in Fig 2 In this way we found the PPA-A and PPA-B for each
platelet concentration These data were plotted in the inset. The open circles (-O-) give the results for PPA-B and closed circles (-O-) for PPA-A
Flg. 4 Assessment of procoagulant phospholipids in whole blood Several blood samples were collected in 3 870 sodium citrate (1 part citrate, nine parts blood)
Blood was diluted 20 times in isotonic salt and then the phospholipid related activity was measured as in Fig I The reaction was stopped by sub-sampling in
500 pl of either TrisA.{aCl + l0 mM EDTA (pH 7.9), or 100 mM ammonium bicarbonate, 10 mM EDTA (pH 8.0) In case of sub-sampling in TriVNaCl-EDTA
the red cells were spun down and thrombin was measured in the supernatant. In the second case the centrifuge-step was omitted and thrombin was after 2 min to
al1ow complete lysis of the erythocytes. The hydrolysis rate in Tris'buffer is given on the x-axis and the hydrolysis rate in ammonium bicarbonate buffer (lyse
buffer) is given on the y-axis
0.0
0.0 o.4 0.8 1.2 1.6 2.0
Hydrolysis rates in Tris-buffer (AA/min)
the formed thrombin within a few minutes, because the present ATIII
inactivates the thrombin at a rate of approximately 0.57o per min.
Both the factor V released from platelets during activation (26,21),
and the plasma factor V might affect the assay. To study the effect of
factor V on this assay we have added factor V to samples with a low
concentration of procoagulant phospholipids and performed the assay
Table I Phospholipid related activity in whole blood and washed erythrocytes Blood from two healthy volunteers was collected on ACD. Pafi of the blood was
used to prepare rvashed erythrocytes (packed cel1s) The whole blood was diluted 20X and the packed cells 50X in isotonic salt. Then the PPA was determined.
The values for the erythrocytes were conected for the hematocrit (HCT) of the blood, i. e. X HCT/0.40. The diluted blood/erythrocytes was incubated uring 5 mtn
at37"Cwith3pI{prothrombin(i),with3pMprothrombin+5pg/mlcol lagen(i i) ,with3pMprothrombin+4.5nMthrombin(i i i ) ,orwith3pMprothrombin
+ 5 pg/collagen + -1.5 nM thrombin (iv). The data were conected for thrombin formation in the absence of bloodierytluocytes
E*p. Pretreatment Whole blood
PPA-A PPA-B
(nM/min2) (nM/min)
Washed erythrocytes
PPA-A PPA-B
(nM/min2) (nM/min)
(i) no
(ii) collagen
(iii) thrombin
(iv) coll + tlromb
(i) no
(ii) collagen
(iii) thrombin
(iv) coll + thromb
0.0
0 043
0.075
0 28r
0 126
0.095
0292
0 659
0.120
0 .110
0.098
0.095
0.410
0 396
0.328
0.556
0.0
0.017
0 019
0 0
0.007
0 021
0 0
0.007
0. tT7
0.172
0.147
0.r93
0 152
0.081
0.1 84
0.109
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Flg 5 Determination of PPA in whole blood of normals and patients treated
for thrombotic disease with sintromitis. In all cases the blood was collected on
ACD. The PPA-A and PPA-B were determined as in Fig 2, however, samples
were taken each 30 sec In the left part of the figure the values for PPA-B of
normals (11cases) and patients (9cases) are plotted in vertical box plots,
which gives the mean (thick line) of the PPA-B values, the 95Va and 5Vo per-
centile values (captions). the 757c and25Vo percentlle values (box) and the 50%
percentile value (thin line. which sometimes falls under the thick line) In the
right part of the figure the values for PPA-A of normals and patients are plot-
ted in box plots The age of both the normals and patients was between 50 and
70 years
Table 2 The effect of FV on the platelet assay. Samples were prepared with
phospholipid vesicles (75% PC;2570 PS) and variable amounts of factor V
The assay was done as described in Fig 2 The phospholipid concentration i
the reaction mixture was 1 67 nM
Discussion
The purpose of this article is to describe the development of a rapid
and simple test to determine one 0f the three essential thrombin based
feedback mechanisms of blood coagulation, i. e. the generation 0f
platelet related procoagulant activity (PPA-A), as well as the basal
phospholipid related procoagulant activity 0f untriggered blood (PPA-B).
The PPA is measured in a system in which the reaction rate is limited
by procoagulant phospholipids. It is well documented that a membrane
becomes more procoagulant when PS is exposed in the outer leaflet of
the membrane (1-4), for that reason it is very likely that an increase of
the reaction rate during the test is due to exposure of PS in the outer
leaflet of the platelets. The increase of the reaction rate was found only
in the cases when the reaction mixture contained platelets.
The test is essentially a measurement of he amounts ofprocoagulant
phospholipids present and developing in the sample. By using 0.4 nM
factors Xu and \ (final concentration) the assay is very sensitive and
linear in procoagulant phospholipids (2570P5,15%PC) up to 10 nM
Rosing et al. (9) showed that in the absence of phospholipids the \ of
the prothrombinase forprothrombin isabout 35 pM, whereas this num-
ber decreases to 32 nM in the presence of 2.6 pM phospholipids. This
means that by using 2 pM prothrombin the formed FX"-F{-PL-com-
plex is completely saturated with prothrombin and thus thrombin
formation is not limited by prothrombin. To make the test as simple and
sensitive as possible reagents 1and 2 (see "Execution ofthe PPA{est in
PRP or whole blood") were prepared with compositions based on the
results obtained inFig. 1.
With the reagents 1and 2 tests were done with both isolated plate-
lets, whole blood and PRP. In Fig.2 we show that isolated platelets
have a low phospholipid related procoagulant activity. The PPA-B ac-
tivity is not significantly increased by preincubation of the platelets
with thrombin, coiiagen, or a combinaton of both. However, the
PPA-A is increased with thrombin 0r collagen and more significantly
by the combination of both, which is in agreement with the literature
(1, 28). This result is to be expected because during the preincubation
step no Ca-ions were present, which are required for the flip-flop reac-
tion and thus for the development 0f a procoagulant platelet membrane.
Only when the platelets are recalcified, i. e. on addition of the FX,-FV,-
Ca-mixture, the effect of thrombin and/or collagen will develop. The
increase 0f the PPA-A cannot be due to the effect of released factor V.
The platelet count in the reaction mixture was 4.2 x 10e cells,4. This
amount of platelets can release 0.032 nM factor V (see ref. 29), which
can increase the PPA-A maximally 0.01.
Fig. 3 has shown that the PPA is proportional with the platelet count,
thus it is allowed to compare different samples provided that cor-
rections are made for the piatelet count. The platelet count in this ex-
periment maximally was 16.7 x lOecells/l, so less than 0.125nM
factor V was released (see ref. 29), or the maximal effect on the PPA-A
was 0.025. or less than 270 of the calculated PPA-A.
An important simplification of the test procedure is achieved by
using ammonium bicarbonate + EDTA as stop-buffer. It was shown
Fig, a) that erythrocytes lyse in this buffer and there is no need to
centrifuge the blood before the thrombin can be measured. Because the
haemoglobin has a high absorption it is necessary to dilute the blood
sufficiently. In practice we found that a final dilution of 60X was suffi-
cient. Other advantages 0f this high dilution are (i) the determination of
PPA in PRP is not disturbed by clotting of the plasma, which is some
cases till occurs when the platelet count is high, (ii) the citrate in the
sample is diluted to less than 0.3 mM and only a very small effect on
the prothrombinase byreducing the calcium concentration is expected,
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as described in Fig. 2. Then the PPA-A and PPA-B was determined by
curve fitting. The results are given in Table 2. One can notice that the
basal activity is not affected by factor V, however, the PPA-A increases
from 0.17 to 0.38 by increasing the factorV concentration from 0 to
0.8 nM.
Normal Values and Some Preliminary Data on Patient Samples
We did a preliminary experiment to test the usefulness of the test as
a routine assay. We measured the activity of a small group of normals
and of a group of patients a previous (more than 6 months ago) myo-
cardial infarction, which for that reason were treated with sintromitis at
the Thrombosis Service of the Academic Hospital of Maastricht. In
Fig 5 it is seen that the PPA-B activity of whole blood is higher in this
group than in a group of age matched healthy volunteers.
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(iii) the ATIII is diluted so much that thrombin inactivation is slow
(about 0.5% per min), which makes the thrombin determination more
reliable, and (iv) coagulation reactions other than prothrombinase have
become negligible, because the components which cause these re-
actions are diluted; in fact we found no difference in a blank with
isotonic salt and with normal platelet-poor plasma.
The preliminary clinical study has shown a remarkable result.
Patients with a thrombotic disease have a significant higher PPA than
healthy control subjects. Because both groups are of the same age there
is no need t0 conect for age. The mean PPA-B of the patient and
control group were 1.010 t 0 441 and 0.445 x 0.126, respectively
and the mean of the PPA-A of both groups were 0.216 t 0.075 and
0.148 t 0.050, respectively. These figures show that the PPA-B of the
patients is significant higher than the PPA-B of the controls. The differ-
ence between the PPA-A of patients and controls is less, however, the
mean of the patient group still is about 1.5 X higher. These xperiments
are done with diluted PRP and thus the reaction mixture contains plas-
ma factor V. The dilution was 60X and thus about 0.25 nM factor V
will be present. Table 2 shows that this amount offactor V increases the
PPA-A for about 0.05. This number is negligible with the measured
values.
The main goal of this afiicle was the development of a sensitive and
rapid assay to measure procoagulant phospholipids in whole biood and
plasma. The described test procedure is suitable [0 measure in a clinic
the procoagulant phospholipids in whole blood and/or plasma as was
shown in the small pilot study The factor V, concentration i the test
mixture is 0.4 nM. For that reason the effect of platelet-released factor
V or plasma factor V is very small, however, it has to be taken tn mrnd
that factor V can affect the assay when it is present in high concen-
trations (see Table 2). The results obtained in the pilot study are very in-
teresting and for that reason the study must be extended to confirm the
preliminary data. These studies fall outside the scope of this article.
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